Tracers / [89Zr]DFO-F8
[89Zr]DFO-F8
Also written as [Zr-89]Zr-DFO-F8
- Radionuclide
- Zr-89 t½ 4704 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 2
What it is
- Compound class
- DFO-conjugated F8 antibody targeting extra domain A of fibronectin (immuno-PET/theranostic construct)
- Target / mechanism
- Extra domain A of fibronectin (extracellular matrix protein overexpressed in TNBC stroma) PMID 41537706
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | — | — | p-SCN-Bn-DFO Macrocyclics | 41537706 2026 Clin Cancer Res F8 was buffer exchanged into PBS (pH 8.5) prepared with chelex 100 resin via a 50 kDa MWCO Amicon spin filter, and incubated with p-SCN-Bn-DFO (Macrocyclics #B-705) in a 1:6 molar ratio at 37 °C and 300 rpm for 60 minutes. |
| — | — | — | — | >99% | DFO-B7-H3mab | 41207336 2026 Eur J Pharm Sci |
Need this precursor?We can point you to suppliers for [89Zr]DFO-F8, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41537706. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41537706: 'p-SCN-Bn-DFO (Macrocyclics #B-705)'.